stockrowDelcath Systems, Inc.
DCTH Healthcare Medical Devices
Delcath Systems, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $85.2 million, up 129.1% from fiscal 2024.
- Revenue
- +20.6%
- EPS
- −12.5%
- Free cash flow
- −24.5%
Quarter to June 2026, against a year earlier
Follow DCTH
Alert me
Delcath Systems, Inc. (DCTH) EV/Sales
As of 6 November 2026, Delcath Systems, Inc. (DCTH) trades at a EV/Sales of 4.7×. Over the past ten years it has ranged from −8.8× (June 2017) to 27,556,692,034× (January 2015); the current reading is higher than 37% of that period. That is above the Medical Devices industry median of 2.7× and above the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 3.2× | (59.23%) |
| FY2024 | 7.8× | (55.22%) |
| FY2023 | 17.5× | 78.57% |
| FY2022 | 9.8× | (19.66%) |
| FY2021 | 12.2× | (14.87%) |
| FY2020 | 14.4× | — |
| FY2019 | −4.8× | — |
| FY2018 | 1.2× | 194.54% |
| FY2017 | 0.4× | (100.00%) |
| FY2016 | 256,202× | (84.57%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 3.8× | 37.38% |
| Mar 2026 | 2.7× | (14.67%) |
| Dec 2025 | 3.2× | (16.26%) |
| Sep 2025 | 3.8× | (34.16%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CERS Cerus Corporation compare | 1.7× |
| BWAY Brainsway Ltd. Sponsored ADR compare | 2.4× |
| NPCE NeuroPace, Inc. compare | 4.5× |
| DCTH Delcath Systems, Inc. | 4.5× |
| MASS 908 Devices Inc. compare | 4.9× |
| SGHT Sight Sciences, Inc. compare | 5.6× |
| SSII SS Innovations International, Inc. compare | 7.1× |
| SENS Senseonics Holdings, Inc. compare | 8.3× |
| AVR Anteris Technologies Global Corp. compare | 128× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)